Literature DB >> 20638256

Isoflavones isolated from red clover (Trifolium pratense) inhibit smooth muscle contraction of the isolated rat prostate gland.

A Brandli1, J S Simpson, S Ventura.   

Abstract

This study investigated whether red clover contains any bioactive constituents which may affect contractility of rat prostatic smooth muscle in an attempt to determine whether its medicinal use in the treatment of benign prostatic hyperplasia is supported by pharmacological effects. A commercially available red clover extract was chemically fractionated and various isoflavones (genistein, formononetin and biochanin A) were isolated from these fractions and their effects on contractility were examined on preparations of the isolated rat prostate gland. Contractile effects of the isolated fractions were compared with commercially available isoflavones (genistein, formononetin and biochanin A). Pharmacological tools were used to investigate the mechanism of action modifying smooth muscle contraction. Crude red clover extract (Trinovin) inhibited electrical field stimulation induced contractions of the rat prostate across a range of frequencies with an IC(50) of approximately 68 microg/ml. Contractions of the rat prostate elicited by exogenous administration of acetylcholine, noradrenaline or adenosine 5'-triphosphate (ATP) were also inhibited. Chromatographic separation, and final purification by high performance liquid chromatography (HPLC) permitted the isolation of the isoflavones: daidzein, calycosin, formononetin, prunetin, pratensin, biochanin A and genistein. Genistein, formononetin and biochanin A (100 microM) from either commercial sources or isolated from red clover extract inhibited electrical field stimulation induced contractions of the isolated rat prostate. It is concluded that isoflavones contained in red clover are able to inhibit prostatic smooth muscle contractions in addition to their antiproliferative effects. However, the high concentrations required to observe these smooth muscle relaxant effects mean that a therapeutic benefit from this mechanism is unlikely at doses used clinically. Crown Copyright 2010. Published by Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638256     DOI: 10.1016/j.phymed.2010.05.006

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  6 in total

Review 1.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

2.  Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats.

Authors:  Shan Sasidharan; Srinivasakumar Kp; Amiya Bhaumik; Sreemoy Kanti Das; Hareebndran Nair J
Journal:  Res Rep Urol       Date:  2022-05-26

Review 3.  A Review of the Phytochemistry and Bioactivity of Clover Honeys (Trifolium spp.).

Authors:  Sharmin Sultana; Kevin Foster; Lee Yong Lim; Katherine Hammer; Cornelia Locher
Journal:  Foods       Date:  2022-06-27

4.  Effect of Boerhaavia diffusa in experimental prostatic hyperplasia in rats.

Authors:  Bhavin A Vyas; Niket Y Desai; Paras K Patel; Shrikant V Joshi; Dinesh R Shah
Journal:  Indian J Pharmacol       Date:  2013 May-Jun       Impact factor: 1.200

Review 5.  Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia.

Authors:  Kensuke Mitsunari; Yasuyoshi Miyata; Tomohiro Matsuo; Yuta Mukae; Asato Otsubo; Junki Harada; Tsubasa Kondo; Tsuyoshi Matsuda; Kojiro Ohba; Hideki Sakai
Journal:  Molecules       Date:  2021-01-16       Impact factor: 4.411

6.  Purinergic smooth muscle contractions in the human prostate: estimation of relevance and characterization of different agonists.

Authors:  Annabel Spek; Bingsheng Li; Beata Rutz; Anna Ciotkowska; Ru Huang; Yuhan Liu; Ruixiao Wang; Frank Strittmatter; Raphaela Waidelich; Christian G Stief; Martin Hennenberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-01-11       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.